The predictive value of preoperative neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index for organ failure following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective analysis
DOI:
https://doi.org/10.18203/2349-2902.isj20253829Keywords:
Organ failure, Post-operative, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Intensive careAbstract
Background: Several inflammation-based scores such as neutrophil-to-lymphocyte ratio (NLR) monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) have been identified as new prognosticators in several tumors. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a complex procedure with the potential for high morbidity. Our aim is to analyze if biomarkers can be predictor of organ failure after CRS-HIPEC.
Methods: A retrospective analysis of all patients admitted to our intensive care unit (ICU) following CRS-HIPEC. The primary endpoint was the need for organ support. Variables considered statistically significant in the univariable analysis were included in a logistic regression.
Results: Among 107 patients admitted to the ICU after CRS-HIPEC, 44.8% had organ failure. Patients with postoperative organ failure had higher preoperative NRL and SII. However, these ratios did not independently predict organ failure. Peritoneal cancer index (PCI) was the only significant predictor of organ failure (OR 1.077, p=0.005).
Conclusions: This study highlights the complex interplay between systemic inflammation and organ failure following CRS-HIPEC. Although NLR and SII reflected an inflammatory response in patients who developed organ failure, they did not emerge as independent predictors after adjustment for other variables. In contrast, the PCI effectively stratified risk, underscoring the importance of preoperative assessment of disease burden. These findings emphasize the critical role of ICU admission for postoperative monitoring in this high-risk population, as most patients with organ failure experienced multiple organ dysfunction and higher mortality during ICU stay. Overall, inflammatory biomarkers were not found to be significant predictors of organ failure after CRS-HIPEC.
Metrics
References
Noiret B, Piessen G, Eveno C. Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: A systematic review. Pleura Peritoneum. 2022;7(2):51-61. DOI: https://doi.org/10.1515/pp-2021-0152
Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Sem Surg Oncol. 1998;14(3):254-61. DOI: https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U
Khan H, Johnston FM. Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease. J Surg Oncol. 2022;125(7):1176-82. DOI: https://doi.org/10.1002/jso.26894
Lim PQ, Han IH, Seow KM, Chen KH. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers. Int J Molecul Sci. 2022;23(17):10078. DOI: https://doi.org/10.3390/ijms231710078
Leijte GP, Custers H, Gerretsen J, Heijne A, Roth J, Vogl T, et al. Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated with Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Front Immunol. 2018;9:663. DOI: https://doi.org/10.3389/fimmu.2018.00663
Wajekar AS, Solanki SL, Patil VP. Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of the literature. World J Crit Care Med. 2022;11(6):375-86.
Kang Y, Zhu X, Lin Z, Zeng M, Shi P, Cao Y, et al. Compare the Diagnostic and Prognostic Value of MLR, NLR and PLR in CRC Patients. Clinical Lab. 2021;67(9):NA. DOI: https://doi.org/10.7754/Clin.Lab.2021.201130
Li Q, Geng S, Zhang X, Jia Z. Significance of tumor markers combined with neutrophil to lymphocyte ratio, D-dimer and T-lymphocyte in the diagnosis of colon cancer. Pak J Med Sci. 2023;39(4):1003-7. DOI: https://doi.org/10.12669/pjms.39.4.7157
Ren Z, Yang J, Liang J, Xu Y, Lu G, Han Y, et al. Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic value for recurrent and metastatic breast cancer. Front Surg. 2023;9: 927491. DOI: https://doi.org/10.3389/fsurg.2022.927491
Zhang Y, Jiang C, Li J, Sun J, Qu X. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma. Clin Translat Oncol. 2015;17(10):810-8. DOI: https://doi.org/10.1007/s12094-015-1310-2
Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. In Oncotarget. 2017;8(43):75381-8. DOI: https://doi.org/10.18632/oncotarget.18856
Paulo J, Oliveira J, Silva M, Silva P, Leite Fi, Valente R, et al. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Analysis of Perioperative Risk Factors and Impact on Outcome. Cureus. 2022;14(3):e22937. DOI: https://doi.org/10.7759/cureus.22937
Harper MM, Kim J, Pandalai PK. Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies. J Clin Med. 2022;11(10):2840. DOI: https://doi.org/10.3390/jcm11102840
Zhou S, Feng Q, Zhang J, Zhou H, Jiang Z, Liu Z, et al. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. BMC Cancer. 2021;21(1):41. DOI: https://doi.org/10.1186/s12885-020-07756-7
Tabrizian P, Jibara G, Shrager B, Franssen B, Yang MJ, Sarpel U, et al. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surgical Oncol. 2013;22(3):184-9. DOI: https://doi.org/10.1016/j.suronc.2013.06.001
Birgisson H, Enblad M, Artursson S, Ghanipour L, Cashin P, Graf W. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2020;46(12):2283-91. DOI: https://doi.org/10.1016/j.ejso.2020.07.039
Deo S, Ray M, Bansal B, Bhoriwal S, Bhatnagar S, Garg R, et al. Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases. World J Surg Oncol. 2021;19(1):164. DOI: https://doi.org/10.1186/s12957-021-02276-5
Bai M, Li Y, Pu H, Xu Y, Chen J, Xu H, et al. Optimal peritoneal cancer index cutoff point for predicting surgical resectability of pseudomyxoma peritonei in treatment-naive patients. World J Surg Oncol. 2024;22(1):39. DOI: https://doi.org/10.1186/s12957-024-03318-4
Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Sem Surg Oncol. 2005;2(1):3. DOI: https://doi.org/10.1186/1477-7800-2-3
Wajekar AS, Solanki SL, Patil VP. Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of the literature. World J Crit Care Med. 2022;11(6):375-86. DOI: https://doi.org/10.5492/wjccm.v11.i6.375
Medina Fernández FJ, Muñoz-Casares FC, Arjona-Sánchez A, Casado-Adam A, Gómez-Luque I, Garcilazo Arismendi DJ, et al. Postoperative Time Course and Utility of Inflammatory Markers in Patients with Ovarian Peritoneal Carcinomatosis Treated with Neoadjuvant Chemotherapy, Cytoreductive Surgery, and HIPEC. Ann Surg Oncol. 2015;22(4):1332-40. DOI: https://doi.org/10.1245/s10434-014-4096-5
Wang X, Li T. Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer. World J Surg Oncol. 2020;18(1):62. DOI: https://doi.org/10.1186/s12957-020-01842-7
Chua TC, Yan TD, Saxena A, Morris DL. Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure? Ann Surg. 2009;249(6):900-7. DOI: https://doi.org/10.1097/SLA.0b013e3181a45d86
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature, 2008;454(7203):436-44. DOI: https://doi.org/10.1038/nature07205
Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and Colon Cancer. Gastroenterology. 2010;138(6):2101-14. DOI: https://doi.org/10.1053/j.gastro.2010.01.058
Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in cardiovascular diseases: An early indicator of prognosis? Exp Molecul Pathol. 2019;110:104267. DOI: https://doi.org/10.1016/j.yexmp.2019.104267
Kim NY, Chun DH, Kim SY, Kim NK, Baik SH, Hong JH, et al. Prognostic value of systemic inflammatory indices, NLR, PLR, And MPV, for predicting 1-year survival of patients undergoing cytoreductive surgery with HIPEC. J Clin Med. 2019;8(5):589. DOI: https://doi.org/10.3390/jcm8050589
Amroun K, Scholer V, Djerada Z, Renard Y, Bouche O, Rhaiem R, et al. Inflammatory biomarkers to predict postoperative infectious complications after cytoreductive surgery and HIPEC for peritoneal carcinomatosis. Eur J Surg Oncol. 2022;48(2):455-61. DOI: https://doi.org/10.1016/j.ejso.2021.09.015
El Asmar A, Delcourt M, Kamden L, Khaled C, Bohlok A, Moreau M, et al. Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases. Ann Surgical Oncol. 2023;30(3):1863-9. DOI: https://doi.org/10.1245/s10434-022-12736-1
Hung HC, Hsu PJ, Chang TC, Chou HH, Huang KG, Lai CH, et al. Neutrophil-to-lymphocyte-ratio-based perioperative prognosis prediction model on early mortality after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Asian J Surg. 2022;45(12):2676-85. DOI: https://doi.org/10.1016/j.asjsur.2022.01.104
Downloads
Published
How to Cite
Issue
Section
